Published Studies Related to Dtic-Dome (Dacarbazine)
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for
patients with stage III/IV melanoma. 
in this trial... CONCLUSION: During the first year of study, there was little difference between
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line
treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised
dacarbazine with dacarbazine alone... INTERPRETATION: Selumetinib plus dacarbazine showed clinical activity in patients
A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. [2011.07.26]
BACKGROUND: alpha(v) integrins are involved in angiogenesis and melanoma tumourigenesis. Intetumumab (CNTO 95) is a fully human anti-alpha(v)-integrin monoclonal antibody... CONCLUSION: With its favourable safety profile and a nonsignificant trend towards improved OS, intetumumab merits further investigation in advanced melanoma.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. [2011.06.30]
BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma... CONCLUSIONS: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.).
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. [2011.06.20]
PURPOSE: To assess the activity and toxicity of the combination of gemcitabine plus dacarbazine (DTIC) in patients with advanced soft tissue sarcoma (STS) in a randomized, multicenter, phase II study using DTIC alone as a control arm... CONCLUSION: The combination of gemcitabine and DTIC is active and well tolerated in patients with STS, providing in this phase II randomized trial superior progression-free survival and overall survival than DTIC alone. This regimen constitutes a valuable therapeutic alternative for these patients.
Clinical Trials Related to Dtic-Dome (Dacarbazine)
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma [Active, not recruiting]
The purpose of this clinical research study is to examine the safety and effectiveness (how
well the drug works) of two different treatments for patients with melanoma. One treatment
is an investigational compound (a drug that is not currently approved by the United States
Food and Drug Administration [FDA]), know as ipilimumab (also known as MDX-010 or BMS-734016)
together with an approved chemotherapy drug called dacarbazine
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma [Recruiting]
This Phase II clinical study is an open-label, multicenter study of L19IL2 in combination
with Dacarbazine in patients with metastatic melanoma.
The study is divided in two parts: a phase IIa part, designed to establish the recommended
dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine, as
well as to determine the preliminary tolerability profile; the second phase IIb part
evaluates the objective response rate (ORR) including a randomized study with a fixed dose
of Dacarbazine with or without L19IL2, dosed at the RD determined in phase IIa.
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma [Recruiting]
The main purpose of this research study is to compare the safety, tolerability, and anti
tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with
metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new
preparation of the active drug paclitaxel. It contains the same medication as the
prescription chemotherapy drug Abraxane®. Abraxane® is approved by the FDA for the
treatment of metastatic breast cancer after failure of combination chemotherapy for
metastatic disease or relapse within 6 months of adjuvant chemotherapy. Dacarbazine is
approved by the FDA for the treatment of melanoma. In this study, ABI-007 and Dacarbazine
will be tested as therapy for people who have not yet had any cancer treatment for the
diagnosis of metastatic melanoma.
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma [Recruiting]
- Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of E7080
administered in combination with dacarbazine.
- Phase II: To evaluate the safety and tolerability of E7080 administered in combination
with dacarbazine, compared with dacarbazine alone.
â€¢ Phase II: to make a preliminary assessment of the efficacy of E7080 administered in
combination with dacarbazine, compared with dacarbazine alone.
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267AM2)(COMPLETED) [Completed]
The purpose of this study is to ascertain if the extended schedule of Temozolomide, which
allows increased doses and potential depletion of the enzyme underlaying resistance, is a
more effective treatment of metastatic melanoma than single agent dacarbazine.